Plan B Decision Mobilizes House Members To Seek FDA Integrity Review
This article was originally published in The Pink Sheet Daily
Executive Summary
A bill directing the agency to conduct a formal review of its decision-making process in turning down the Rx-to-OTC switch application for the emergency contraceptive is slated to be introduced May 13 by Rep. Maloney.
You may also be interested in...
Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure
Outgoing US FDA Office of New Drugs director tells the Pink Sheet being on the outside will take some adjustment.
Plan B GAO Investigation Sought By House Members
Group led by Rep. Waxman is requesting that GAO examine communications between the White House and HHS regarding FDA's decision not to approve the Plan B emergency contraceptive switch application.
Plan B GAO Investigation Sought By House Members
Group led by Rep. Waxman is requesting that GAO examine communications between the White House and HHS regarding FDA's decision not to approve the Plan B emergency contraceptive switch application.